Related Experiment Video

Updated: Feb 3, 2026

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.3K

Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer

Neesha C Dhani1, Amit M Oza2

  • 1Department of Medicine, University of Toronto, ON, Canada; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Avenue, Suite 7-817, Toronto, ON M5G 1Z5, Canada.

Hematology/Oncology Clinics of North America
|November 5, 2018
PubMed

Insights

Epithelial ovarian cancer is a deadly disease. Novel antiangiogenic therapies combined with biologics show promise for improving survival rates and reducing toxicity in front-line treatment.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Biology

Background:

  • Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer mortality.
  • Current treatments often involve cytotoxic combinations with significant toxicities.
  • Improved therapeutic ratios are needed, particularly in front-line settings.

Purpose of the Study:

  • To evaluate the role of antiangiogenic therapies in epithelial ovarian cancer.
  • To explore novel combinations of cytotoxic agents with biologics.
  • To prioritize front-line treatment strategies due to severe adverse events in advanced disease.

Main Methods:

  • Review of current data on angiogenesis as a therapeutic target in EOC.
  • Analysis of clinical trial outcomes for cytotoxic/biologic combinations.
  • Assessment of safety profiles, focusing on gastrointestinal perforation/fistula.

Main Results:

  • Angiogenesis is a critical process in EOC and a viable drug target.
  • Antiangiogenic agents are increasingly recognized as essential in EOC treatment.
  • Novel combinations aim to enhance efficacy while managing toxicity.

Conclusions:

  • Antiangiogenic therapies should be a cornerstone of epithelial ovarian cancer treatment.
  • Front-line strategies incorporating novel combinations are a priority.
  • Ongoing research focuses on developing new biologic combinations for improved patient outcomes.
Keywords:
AngiogenesisBevacizumabMaintenanceOvarian cancerVascular endothelial growth factor (VEGF)

More Related Videos

Measuring Active and Passive Tameness Separately in Mice07:13

Measuring Active and Passive Tameness Separately in Mice

Published on: August 10, 2018

7.6K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.8K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.5K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.9K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.3K